Mesenchymal stem cell (MSC)-based therapy using gene delivery systems has been suggested for degenerative diseases. Although MSC-based clinical applications are effective and safe, the mode of action remains unclear. Researchers have commonly applied viral-based gene modification because this system has efficient vehicles. While viral transfection carries many risks, such as oncogenes and chromosomal integration, nonviral gene delivery techniques are less expensive, easier to handle, and safe, although they are less efficient. The electroporation method, which uses Nucleofection technology, provides critical opportunities for hard-to-transfect primary cell lines, including MSCs. Therefore, to improve the therapeutic efficacy using genetically modified MSCs, researchers must determine the optimal conditions for the introduction of the Nucleofection technique in MSCs. Here, we suggest optimal methods for gene modification in PD-MSCs using an electroporation gene delivery system for clinical application.

中文翻译：

---

基于非病毒电穿孔的胎盘来源间充质干细胞中基因修饰的功效。

已经提出了使用基因递送系统的基于间充质干细胞（MSC）的疗法治疗退行性疾病。尽管基于MSC的临床应用是有效且安全的，但作用方式仍不清楚。研究人员通常应用基于病毒的基因修饰，因为该系统具有高效的载体。尽管病毒转染具有许多风险，例如致癌基因和染色体整合，但非病毒基因递送技术虽然效率较低，但价格便宜，易于操作且安全。使用Nucleofection技术的电穿孔方法为难以转染的原代细胞系（包括MSC）提供了关键的机会。因此，为了使用转基因的MSC改善治疗效果，研究人员必须确定在MSC中引入核转染技术的最佳条件。在这里，我们建议使用电穿孔基因传递系统进行临床应用的PD-MSCs基因修饰的最佳方法。